Real world study of sacituzumab govitecan in metastatic triple-negative breast cancer in the United Kingdom

Hanna, D., Merrick, S., Ghose, A. et al. (24 more authors) (2024) Real world study of sacituzumab govitecan in metastatic triple-negative breast cancer in the United Kingdom. British Journal of Cancer, 130 (12). pp. 1916-1920. ISSN 0007-0920

Abstract

Metadata

Item Type: Article
Authors/Creators:
  • Hanna, D.
  • Merrick, S.
  • Ghose, A.
  • Devlin, M.J.
  • Yang, D.D.
  • Phillips, E.
  • Okines, A.
  • Chopra, N.
  • Papadimatraki, E.
  • Ross, K.
  • Macpherson, I.
  • Boh, Z.Y.
  • Michie, C.O.
  • Swampillai, A.
  • Gupta, S.
  • Robinson, T.
  • Germain, L.
  • Twelves, C.
  • Atkinson, C.
  • Konstantis, A.
  • Riddle, P.
  • Cresti, N.
  • Naik, J.D.
  • Borley, A.
  • Guppy, A.
  • Schmid, P.
  • Phillips, M.
Copyright, Publisher and Additional Information:

© The Author(s) 2024. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http:// creativecommons.org/licenses/by/4.0/.

Keywords: Biomedical and Clinical Sciences; Oncology and Carcinogenesis; Cancer; Women's Health; Breast Cancer; Patient Safety; Clinical Research; Clinical Trials and Supportive Activities; Evaluation of treatments and therapeutic interventions; Pharmaceuticals; Cancer; Humans; Triple Negative Breast Neoplasms; Middle Aged; Female; Aged; Antibodies, Monoclonal, Humanized; Adult; United Kingdom; Camptothecin; Retrospective Studies; Aged, 80 and over; Neoplasm Metastasis; Immunoconjugates
Dates:
  • Published: 29 June 2024
  • Published (online): 24 April 2024
  • Accepted: 5 April 2024
Institution: The University of Leeds
Academic Units: The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Leeds Institute of Medical Research (LIMR) > Division of Oncology
Funding Information:
Funder
Grant number
Cancer Research UK Supplier No: 138573
C37059/A12513
Cancer Research UK Supplier No: 138573
C37059/A12513
Cancer Research UK Supplier No: 138573
C37059/A12513
Cancer Research UK Supplier No: 138573
C37059/A12513
Cancer Research UK Supplier No: 138573
C37059/A11941
Cancer Research UK Supplier No: 138573
C37059/A11941
Cancer Research UK Supplier No: 138573
C37059/A12514
Cancer Research UK Supplier No: 138573
C37059/A12514
Cancer Research UK Supplier No: 138573
C64904/A27744
Cancer Research UK Supplier No: 138573
C7852/A19772
Depositing User: Symplectic Publications
Date Deposited: 11 Jul 2024 11:58
Last Modified: 11 Jul 2024 11:58
Published Version: https://www.nature.com/articles/s41416-024-02685-9
Status: Published
Publisher: Springer
Identification Number: 10.1038/s41416-024-02685-9
Related URLs:
Open Archives Initiative ID (OAI ID):

Export

Statistics